UTokyo IPC has invested approximately 300 million JPY in Braizon Therapeutics, a venture utilizing innovative drug delivery technology to penetrate the blood-brain barrier for central nervous system disease treatments.

Target Information

Braizon Therapeutics Inc., a venture established in 2015, focuses on the research and development of pharmaceuticals targeting the central nervous system. Founded as part of a collaboration between the Tokyo Medical and Dental University and the University of Tokyo, Braizon has developed an innovative drug delivery technology designed to penetrate the blood-brain barrier (BBB) using glucose-modified nanoparticles. This technology leverages the natural glucose transport mechanisms within the endothelial cells of the brain to efficiently deliver medications directly to where they are needed most.

Located in Bunkyo, Tokyo, Braizon’s team is led by CEO Mariko Tosu. The company aims to address significant challenges in treating central nervous system disorders, such as dementia, which represent a pressing social issue. By enabling the delivery of various medicinal compounds, including low molecular weight drugs, nucleic acid medicines, and antibodies, Braizon's technology has the potential to revolutionize treatment strategies in neurology.

Industry Overview in Japan

The biopharmaceutical industry in Japan is one of the largest and most advanced in the world, characterized by a strong emphasis on research and innovation. The interplay between academia and industry is vital in driving the development of new therapies, especially in